Solvay discontinues obesity drug
This article was originally published in Scrip
Executive Summary
Solvay's investigational obesity compound SLV319 (ibipinabant), which was in Phase II trials, has become the latest casualty from the cannabinoid type 1 (CB1) antagonist class after the Belgian company decided to discontinue its development.